Page 127 — Blocking the IL-23/Th17/IL-17 inflammatory axis in psoriasis with upstream and downstream biologic therapy
Psoriasis pathogenesis centers on a self-amplifying inflammatory axis. Dendritic cells and keratinocytes in genetically susceptible skin secrete IL-23, a heterodimeric cytokine (p19/p40) that acts on the IL-23 receptor of naive and memory T-cells, driving their differentiation into pathogenic Th17 cells under control of the transcription factor RORγt. Th17 cells expand clonally and secrete IL-17A (and related isoforms IL-17F, IL-17A/F), which binds IL-17 receptors on keratinocytes, fibroblasts, and endothelial cells — triggering the hyperproliferative, inflamed, scaling plaques characteristic of the disease.
The psoriasis cascade proceeds through discrete, druggable steps:
1. Trigger — mechanical trauma (Koebner phenomenon), infection, or stress activates plasmacytoid dendritic cells in the dermis, which produce type I interferons and self-DNA/LL-37 complexes.
2. IL-23 production — activated dendritic cells and macrophages secrete IL-23, the dominant upstream cytokine sustaining the pathogenic Th17 response in chronic plaque psoriasis (distinct from the acute IL-23-independent phase).
3. Th17 differentiation and expansion — IL-23 signals through IL-23R/IL-12Rβ1 on T-cells, activating JAK2/TYK2 → STAT3 signaling, which sustains RORγt expression and clonal expansion of memory Th17 cells resident in psoriatic skin.
4. IL-17 secretion — Th17 cells (and to a lesser extent γδ T-cells, ILC3s, and mast cells) release IL-17A, the principal effector cytokine, into the dermal-epidermal junction.
5. Keratinocyte activation — IL-17 binds IL-17RA/RC on keratinocytes, activating NF-κB and MAPK pathways, inducing antimicrobial peptides (LL-37, β-defensins), chemokines (CXCL1, CXCL8) that recruit neutrophils, and proliferation genes — producing the thickened, scaling, erythematous plaque.
This cascade is self-amplifying: keratinocyte-derived signals feed back to activate more dendritic cells, sustaining chronic plaques without intervention.
The clinical breakthrough insight was that IL-23 — not IL-12 — is the dominant driver sustaining chronic plaque psoriasis. This reframing, validated by the disproportionate efficacy of selective anti-IL-23p19 agents over dual anti-p40 agents in some measures, redirected an entire generation of biologic drug development toward this single axis.
IL-23 inhibitors are monoclonal antibodies that bind the p19 subunit unique to IL-23 (leaving IL-12 and its Th1 functions untouched), preventing IL-23 from engaging its receptor on T-cells. By intervening before Th17 differentiation and expansion occur, this class of biologics reduces the entire downstream supply of pathogenic Th17 cells and their cytokine output at its source — an upstream, cascade-limiting intervention point.
Selective p19-subunit antibodies (guselkumab, risankizumab, tildrakizumab) bind circulating and cell-surface IL-23 with high affinity, sterically preventing its interaction with the IL-23 receptor complex on T-cells and innate lymphoid cells.
Key pharmacologic properties: • Target specificity: p19 subunit is unique to IL-23 (unlike p40, shared with IL-12), so IL-12-driven Th1/interferon-γ responses — important for antimycobacterial and antiviral defense — remain largely intact. • Half-life and dosing interval: long antibody half-lives (~3 weeks) combined with high potency at the cytokine level allow extended maintenance intervals — every 8 or even every 12 weeks after induction dosing. • Downstream consequence: because IL-23 signaling sustains, rather than initiates, resident memory Th17 cells in skin, blockade produces a gradual decline in Th17 cell numbers and IL-17 output rather than an immediate cytokine-level shutdown. • Durability: because the intervention removes the maintenance signal for the pathogenic T-cell population itself, clinical responses to IL-23 blockade tend to be deep and durable, with some patients maintaining clearance well beyond the dosing interval if therapy is interrupted.
Ustekinumab, an earlier dual anti-p40 antibody, blocks both IL-12 and IL-23 and validated the pathway clinically, but selective anti-p19 agents were developed to preserve IL-12/Th1 function while achieving deeper, more durable IL-23-specific blockade.
Because IL-23 blockade acts upstream on the population of pathogenic T-cells rather than only mopping up circulating cytokine, its clinical effect tends to build gradually over the induction period and can persist after individual doses wear off — a distinguishing pharmacodynamic signature versus downstream cytokine-neutralizing agents.
IL-17 inhibitors act directly on the effector cytokine or its receptor, neutralizing inflammatory signaling at the skin regardless of how much IL-17 is being produced upstream by Th17 cells and other sources. Because this intervention point is closer to the tissue effect, onset of clinical response is often faster than upstream approaches, though the effect depends on continuous drug exposure to keep neutralizing newly produced cytokine.
IL-17-targeting biologics fall into two mechanistic groups:
• Cytokine-neutralizing antibodies (secukinumab, ixekizumab): bind circulating IL-17A directly, preventing it from engaging IL-17RA/RC on keratinocytes. Bimekizumab additionally neutralizes IL-17F, blocking both major effector isoforms and achieving deeper responses in head-to-head trials.
• Receptor-blocking antibodies (brodalumab): bind IL-17RA itself, blocking signaling from all IL-17 isoforms (A, F, A/F, and IL-17C) that converge on this shared receptor subunit — a broader downstream blockade than isoform-specific antibodies.
Because this class intercepts the effector cytokine at the tissue level rather than reducing the upstream T-cell population, IL-17 blockade produces rapid, high-magnitude improvement, often visible within 2–4 weeks — the fastest-onset biologic class in psoriasis. However, since Th17 cells continue producing IL-17, clinical control depends on maintaining adequate drug trough levels, typically via more frequent dosing (every 2–4 weeks) than IL-23 blockade.
A distinguishing safety signature of IL-17 pathway blockade is an increased rate of mucocutaneous candidiasis, reflecting IL-17's physiological role in antifungal barrier defense at mucosal surfaces — a mechanistically predictable, generally mild and manageable class effect. IL-17 blockade also carries a caution regarding new or worsening inflammatory bowel disease.
IL-17 blockade's fast onset and IL-23 blockade's durable, deep response reflect their different intervention points on the same cascade — a direct illustration of how upstream versus downstream targeting of one pathway produces distinct clinical pharmacodynamic profiles.
Psoriatic keratinocytes turn over roughly 5–7 times faster than normal skin, cycling from basal layer to shed surface cell in about 3–5 days instead of the normal ~28-day epidermal renewal cycle. This accelerated, disordered proliferation — driven by IL-17-induced NF-κB and STAT3 signaling in keratinocytes — produces the thickened, scaling plaques of psoriasis. Blocking either IL-23 or IL-17 removes the inflammatory drive sustaining this hyperproliferative state, allowing turnover to gradually normalize.
Reversal of keratinocyte hyperproliferation is a downstream, tissue-level consequence of successfully interrupting the IL-23/Th17/IL-17 axis, and unfolds over a longer timescale than the immune-cell-level changes that precede it:
1. Cytokine signal withdrawal — as IL-23 or IL-17 blockade takes effect, keratinocyte exposure to IL-17, TNF-α, and IL-22 falls, reducing NF-κB and STAT3-driven transcription of proliferation and antimicrobial peptide genes.
2. Reduced epidermal thickness — acanthosis (epidermal thickening) and parakeratosis (retained nuclei in the stratum corneum, a hallmark of abnormally rapid turnover) begin to resolve as keratinocyte division rate slows toward baseline.
3. Vascular and immune infiltrate regression — the dilated, tortuous dermal papillary capillaries and neutrophilic/lymphocytic infiltrate that sustain the visible erythema and scale also regress as the inflammatory drive subsides.
4. Clinical-histologic lag — visible plaque thinning generally trails the molecular and cellular changes by several weeks, since already-differentiated keratinocytes in the epidermis must complete their (now-shortened) life cycle and be shed before skin architecture is fully normalized.
Because this is a tissue remodeling process rather than an instantaneous switch, patients typically see progressive thinning and fading of plaques over the induction period rather than immediate resolution — consistent with the gradual clearance curves observed in clinical trials.
Histologic near-normalization of the epidermis is achievable with sustained cytokine blockade — a meaningful distinction from earlier therapies that suppressed visible inflammation without correcting the underlying keratinocyte kinetics, which is one explanation for the deeper and more durable remission seen with modern biologics.
Clinical trials track psoriasis response using the Psoriasis Area and Severity Index (PASI), with PASI75/90/100 representing 75%, 90%, and 100% improvement from baseline. Across biologic classes, most patients show progressive improvement over an induction period of roughly 12–16 weeks, after which maintenance dosing sustains the response — though the shape and speed of the improvement curve differs by mechanism.
The illustrative clearance curve in this simulator reflects two general patterns observed across biologic classes (individual patient response varies substantially and this is not a substitute for clinical data):
• IL-17 blockade — faster initial onset, often producing visible improvement within 2–4 weeks and reaching a substantial fraction of maximum response by week 12, because it acts directly on the tissue-level effector cytokine. Response depth continues to build gradually toward week 16–24 as keratinocyte turnover normalizes.
• IL-23 blockade — slightly slower initial onset because it must first reduce the Th17 cell population and its cytokine output, but often produces deep, highly durable responses by week 16, with some patients maintaining clearance well into extended dosing intervals.
Common milestones tracked in practice and trials: • PASI50 — early signal of response, often visible by week 4–8 • PASI75 — the traditional efficacy threshold for older systemic therapies, typically reached by ~week 12 with modern biologics • PASI90 — the current benchmark for "high bar" response, targeted by week 16 (end of induction) with most modern IL-23 and IL-17 agents • PASI100 — complete skin clearance, achieved by a meaningful subset of patients, often deepening further with continued maintenance therapy beyond 24 weeks
Maintenance-phase relapse after treatment discontinuation varies by mechanism, with some data suggesting more gradual loss of response after stopping IL-23 blockade compared to more rapid relapse after stopping IL-17 blockade — consistent with their different upstream/downstream intervention points on the same cascade.
This timeline is illustrative and simplified for teaching purposes — real-world PASI trajectories vary by individual, biologic agent, dose, and disease severity, and should never be used for clinical decision-making. It demonstrates the general principle that intervention point on a cascade (upstream vs. downstream) shapes the speed and durability of clinical response.